Literature DB >> 15227622

Modified vaccinia Ankara: potential as an alternative smallpox vaccine.

Lewis H McCurdy1, Brenda D Larkin, Julie E Martin, Barney S Graham.   

Abstract

Despite the declaration of smallpox eradication in 1980, the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained. Although the currently available vaccine was used for the most successful medical intervention ever accomplished, it also is associated with side effects that are difficult to accept in a vaccine for a disease that has not been present for >25 years. Herein, we review alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses, and we suggest modified vaccinia Ankara (MVA) as a leading candidate for an alternative smallpox vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15227622     DOI: 10.1086/421266

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

2.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis.

Authors:  U Darsow; M Sbornik; S Rombold; K Katzer; F von Sonnenburg; H Behrendt; J Ring
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-29       Impact factor: 6.166

Review 4.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

5.  Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.

Authors:  Michael S Seaman; Marissa B Wilck; Lindsey R Baden; Stephen R Walsh; Lauren E Grandpre; Colleen Devoy; Ayush Giri; Lizanne C Noble; Jane A Kleinjan; Kristen E Stevenson; Haesook T Kim; Raphael Dolin
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

6.  The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.

Authors:  Jonathan S Duke-Cohan; Kristin Wollenick; Elizabeth A Witten; Michael S Seaman; Lindsey R Baden; Raphael Dolin; Ellis L Reinherz
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

7.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

8.  Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Authors:  Douglas W Grosenbach; Robert Jordan; David S King; Aklile Berhanu; Travis K Warren; Dana L Kirkwood-Watts; Shanthakumar Tyavanagimatt; Ying Tan; Rebecca L Wilson; Kevin F Jones; Dennis E Hruby
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 4.169

9.  Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques.

Authors:  Stephen R Walsh; Jacqueline Gillis; Björn Peters; Bianca R Mothé; John Sidney; Alessandro Sette; R Paul Johnson
Journal:  Vaccine       Date:  2009-06-14       Impact factor: 3.641

Review 10.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.